\

 

 

Home About Us Contact Us

 

Table of Content - Volume 10 Issue 3 - June 2018


 

Lipid profile among newly detected cases of coronary heart disease

 

Ajay Sam Kumar W1, Ram Kumar V2*

 

1Assistant Professor, Department of General Medicine, Mahatma Gandhi Medical College and Research Institute, Pillayarkuppam, Pondicherry 607402, INDIA.

2Assistant surgeon, Tiruparankundram Government Hospital, Madurai, 625005, Tamil Nadu, INDIA.

Email: ajaysamw@gmail.com pvrramkumar@gmail.com

 

REFERENCES

  1. Reddy KS, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005; 366: 1744-9.
  2. Gupta R, Joshi P, Mohan V, Reddy KS, Yusuf S. Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008; 94: 16-26.
  3. McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in South Asians: a review. Clin Epidemiol 1989; 42: 579-609.
  4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
  5. Lawn RM. Lipoprotein (a) in heart disease. Sci Am 1992; 266: 54-60.
  6.  Bhatnagar D, Anand I, Durington PN et al. Coronary risk factors in people from Indian subcontinent in West London and their siblings in India. Lancet 1995; 345: 405-9.
  7. Hopkins PN, Wu L, Hunt S et al. Lipoprotein (a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 2783-92.
  8.  Lamarche B, Tchernof A, Moorjani S et al. Small dense low-density lipoprotein particles as a predictor of the risk of ischaemic heart disease in men. Prospective results from Quebac Cardiovascular Study. Circulation 1997; 95: 69-75.
  9.  Jeppesen J, Hein H, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease: An 8-year followup in the Copenhagen Male study. Arterioscler Thromb Vasc Biol 1997; 17: 1114-20.
  10.  Drexel H, Amann F, Beran J et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of extent of coronary atherosclerosis. Circulation 1994; 90: 2230-5.
  11.  Hamstein A, Walldius G, Szamosi A et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 3-9.
  12. Chambers JC, Elliott P, Zabaneh D, Zhang W, Li Y, Froguel P, et al. Common genetic variation near MC4R is associated with waist circumference and insulin resistance. Nat Genet 2008; 40: 716-8.
  13. Lev-Ran A. Human obesity: an evolutionary approach to understanding our bulging waistline. Diabetes Metab Res Rev 2001; 17: 347-62.
  14. Carlson, L.A.; Bottiger, L.E.; Ahfeldt, P.E. (1979). Risk factors for myocardial infarction in the Stockholm Prospective Study. A 14-year follow-up focusing on the role of plasma triglycerides and cholesterol. Acta Med Scand, 206:351-360.
  15. Castelli, W.P. (1986). The triglyceride issue: a view from the Framingham. Am Heart J, 112:432-437.
  16. Gordon, D.J.; Probstfield, J.L.; Garrison, R.J.; et al. (1989). High-density lipoprotein cholesterol and cardiovascular disease: four prospective american studies. Circulation, 79:8-15.
  17. Ansell, B.J.; Navab, M.; Watson, K.E.; et al. (2004). Anti-inflamatory properties of HDL. Rev Endocr Metab Disord, 5:351-358.
  18. Cui, Y.; Blumenthal, R.S.; Flaws, J.A.; et al. (2001). Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med, 161:1413- 1419.
  19. Manninen, V.; Tenkanen, L.; Koskinen, P.; et al. (1992). Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation, 85:37–45.
  20. Packard, C.J.; Ford, I.; Robertson, M.; et al. (2005). The PROSPER Study Group: Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation, 112:3058–3065.
  21. Labarthe DR (2011). Coronary heart disease, In: Epidemiology and prevention of cardiovascular disease: a global challenge, Labarthe DR, pp. 59-87, Jones and Bartlett, ISBN-13: 978–0– 7637–4689–6, Canada.
  22. Goldstein JL, Hazzard WR, Schrott HG, Bierman EL, Motulsky AG (1973). Hyperlipidemia in coronary heart disease I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest; 52:1533–43.
  23. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH (2009). Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med; 169: 572–8.
  24. Stamler, J, Wentworth, D, Neaton, JD (1986). Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA; 256:2823–8.
  25. Heiss G, Tamir I, Davis CEo (1980). Lipoprotein –Cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation; 61: 302–15.
  26. Glueck CJ, Stein EA (1979). Treatment and management of hyperlipoproteinemia in childhood. In: Levy R, Rifkind B, Dennis B, Ernst N. Nutrition, Lipids, and Coronary Heart Disease, New York: Raven Press; pp. 285–307.
  27.  Bansal S, Buring JE, Rifai N, et al (2007). Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA; 298:309–16.
  28. Abbott RD, Wilson PWF, Kannel WB, Castelli WP (1988). High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: the Framingham Study. Arteriosclerosis; 8: 207–11.
  29. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, et al (2002). Coronary Heart disease in patients with low LDL–cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL– cholesterol and triglycerides as risk factors. Circulation; 105: 1424–8.
  30. Castelli WP (1983). Cardiovascular disease and multifactorial risk: Challenge of the 1980s. Am Heart J; 106: 1191–200.
  31. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttar M, Heinonen OP, et al (1992). Joint effects of serum triglyceride and LDL–cholesterol and HDL– cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation: 85: 37–45.
  32. Kinosian B, Glick H, Garland G (1994). Cholesterol and coronary heart disease: predicting risk s by levels and ratios. Ann Intern Med; 121: 641–7.
  33. Carlson LA, Böttiger LE, Ahfeldt PE (1979). Risk factors for myocardial infarction in the Stockholm prospective study. A 14–year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med Scand;206(5):351–60.
  34. Hokanson IE, Austin MA (1996). Plasma triglyceride level is a risk factor in cardiovascular disease independent of high density lipoprotein cholesterol level: a meta – analysis of population - based prospective studies. J Cardiovasc Risk; 3: 213–9.
  35. Haim M, Benderly M, Brunner D, et al (1999). Elevated serum triglyceride levels and long term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation; 100: 475–82.
  36. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A (2007). Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA; 298:299–308.
Journal Menu MIJOMED Medpulse Manuscript Submission Subscription Aim & Scope Peer Review Process Publication Ethics & Malpractice Statement Open Access Statement Plagiarism Policy Editorial Board Indexing Current Issue Publication Charges Archives Authors Information Copyright & Licensing Privacy Statement Contact Us